Edgar Filing: CYTOKINETICS INC - Form 4

CYTOKINE	ETICS INC									
Form 4	2014									
February 26									OMB A	PPROVAL
FORM	UNITED	STATES		RITIES A			NGE	COMMISSIO	-	3235-0287
Check th if no lon subject to Section 1 Form 4 co Form 5	SECUI	ES IN BENEFICIAL OWNERSHIP OF SECURITIES					January 31, 2005 average urs per . 0.5			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
Cragg David Syn			Symbol	2. Issuer Name and Ticker or Trading ymbol CYTOKINETICS INC [CYTK]			5. Relationship of Reporting Person(s) to Issuer			
(1			3. Date of Earliest Transaction(Month/Day/Year)02/24/2014			(Check all applicable) <u></u> Director <u></u> 10% Owner <u>X</u> Officer (give title <u></u> Other (specify below) <u>below</u>) SVP Human Resources				
				mendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 		
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securi	ties A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	ed Date, if	3. Transactic Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, Amount	ties (A) or of (D) 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Ar
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	iorDerivative	Expiration Date	Underlying Se

Edgar Filing: CYTOKINETICS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title 1
Incentive Stock Option (right to buy)	\$ 9.65	02/24/2014		А	20,481	03/24/2014 <u>(1)</u>	02/24/2024	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 9.65	02/24/2014		А	24,519	03/24/2014(1)	02/24/2024	Common Stock

Reporting Owners

Reporting Owner Name / Address		Relationships						
1 0	Director	10% Owner	Officer	Other				
Cragg David 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94	-080		SVP Human Resources					
Signatures								
David W. Cragg 02/26/2	2014							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) When the ISO and NQ dated 02/24/2014 are combined for a total grant of 45,000 shares, the option shall vest and become exercisable as to 45,000 shares divided into equal monthly installments such that the option shall be 100% vested on 02/24/2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

<u>**</u>Signature of Reporting Person